Financial Trading Blog

5 Stocks Spreadex Traders Fell in Love with



Over the past quarter, the following 5 stocks have been among the most actively traded by Spreadex traders. We rundown the investment case for each.

----------------

Peloton (PTON)

Peleton stock has had a couple of shocking quarters. Which stands to reason after gaining some 850% during the pandemic. Is it ripe to buy the dip or is there worse to come? To get things under control, the board has cut the CEO loose and announced 2,800 job cuts. Has this been done to fix the company? The other possibility is that the firm could be lowering costs to make it a more attractive takeover target. Three giants - Amazon, Apple, and Nike - are rumoured to be considering takeover bids or investments.

Peloton stock currently flirts with its 50-day moving average at $35.

Moderna (MRNA)

Pfizer got most of the headlines for its covid vaccine but having had no previously approved products, Moderna saw a larger boost from covid vaccine sales. Its mRNA vaccine was the first product it brought to market, giving the stock a whopping 2500% at $500 – but has since been more than cut in half. Last quarter, the company cut its sales outlook for the vaccine due to regulatory hurdles. While covid vaccines sales might diminish as the vaccine wanes, the company's cytomegalovirus mRNA vaccine is currently undergoing Phase III trials.

Moderna stock now trading at $160 and below its 100-week moving average.

Easyjet (EZJ)

Last quarter, Easyjet handily beat earnings estimates as European travel remained open despite the surge in omicron. With holiday travel depressed in the previous two years, there is pent-up demand for budget flying. However, the EU announced that the Digital Covid Certificate program would be renewed for another year, which could cap any surge in demand for inter-European travel. Can it sustain the recent rejection and drive the stock towards the $750 zone? If not, traders should focus on the gap down at $560.

EasyJet's share price has crossed above its 200-day moving average, sitting at 675p.

Nvidia (NVDA)

Semiconductor supply is expected to be an issue for the rest of the year, which reduces competitive pressure on Nvidia as demand for chips and graphics cards remains high. A lot of demand for graphics cards is driven by crypto, which might be pressured by a ‘crypto winter’. Nvidia is aiming to disrupt the cloud sector, where firms from Amazon to Google posted record earnings and expect growth to continue. Above its 200-day average, chances of reaching $275 and even $350 again rise. Inversely, crossing below that support, NVDA could find upside pressure at $200, then $180.

Nvidia stock is trading at $239.

Cineworld (CINE)

Cineworld's CEO was optimistic at its last trading update after the firm returned to about 90% of pre-pandemic sales and reported positive cash flow. Traditionally, the first quarter is poor for movies, but the covid situation has disrupted the usual schedule, and the share price is already up 30% this year. Over the next few months, we could see some good box-office pleasers that could push Cineworld's earnings higher, including The Batman, the Tatum/Bullock vehicle, The Lost City, Sonic 2, and Michael Bay's Ambulance. Can the stock get to 56p as a first sign of reversing? Or will the current bounce at its 50-day average prove detrimental for the stock's price down below 30p?

Cineworld share price is currently 39.5p.

DISCLAIMER


Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 64% of retail investors lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money. For professional clients, spread betting and CFD trading can also result in losses larger than your initial stake or deposit.

Spreadex Ltd is authorised and regulated by the Financial Conduct Authority, provides an execution only service and does not provide advice in any way. Nothing within this update should be deemed to constitute the provision of investment advice, recommendations, any other professional advice in any way, or a record of our trading prices. This update does not constitute or form part of an offer of, or solicitation for a transaction in any financial instrument, nor shall it or the fact of its distribution form the basis of, or be relied on in connection with, any contract therefore. Any persons placing trades based on their interpretation of the comments or information within this update does so entirely at their own risk.

No representation, warranty, or undertaking, express or limited, is given as to the accuracy or completeness of the information or opinions contained within this update by Spreadex Ltd or any of its employees and no liability is accepted by such persons for the accuracy or completeness of any such information or opinions. As such, no reliance may be placed for any purpose on the information and opinions contained within this update.

The information contained within this update is the intellectual property of Spreadex Ltd and is protected by UK and International copyright laws. All rights reserved. Users may however freely download, distribute and reproduce extracts of the contents, subject always to accrediting Spreadex Ltd as the source and providing a hyperlink to www.spreadex.com.